ERD-308

Cat. No.: HY-128600

CAS No.: 2320561-35-9

Molecular Formula: $C_{55}H_{65}N_5O_9S_2$

Molecular Weight: 1004

Target: PROTACs; Estrogen Receptor/ERR

Pathway: PROTAC; Vitamin D Related/Nuclear Receptor

Storage: 4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (49.80 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9960 mL	4.9801 mL	9.9602 mL
	5 mM	0.1992 mL	0.9960 mL	1.9920 mL
	10 mM	0.0996 mL	0.4980 mL	0.9960 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1.25 mg/mL (1.25 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 1.25 mg/mL (1.25 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 1.25 mg/mL (1.25 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC_{50} (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively)[1].

IC_{50} & Target

DC50: 0.17 nM (ER in MCF-7 cells), 0.43 nM (ER in T47D ER+ cells)[1].

REFERENCES

[1]. Hu J, et al. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J Med Chem. 2019 Feb 14;62(3):1420-1442.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA